Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21606993 | 0.78 | MAPT (0.35) | OGAMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL21607007 | 0.75 | SMN1; SMN2 (0.36) | OGAMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL20023734 | 0.70 | CYP1A2 (0.44) | OGAALDH1A1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL10052411 | 0.68 | MAPT (0.33) | MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19465804 | 0.68 | POLB (0.39) | OGAMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL21743017 | 0.68 | ALDH1A1 (0.38) | MAPTALDH1A1SMN1; SMN2HPGDPOLB | |
| SCHEMBL10076920 | 0.68 | NPC1 (0.33) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7921134 | 0.67 | SMN1; SMN2 (0.43) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16935052 | 0.66 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL20483576 | 0.66 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-04-29 | — | — | US | disclosed |
| WO-2019243530-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | OGA 1/4885MAPT 7/4885ALDH1A1 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.